InGeneron
Houston, US · Delaware corporation
InGeneron develops regenerative cell therapies that use a patient's adult stem cells and other regenerative cells harvested from fat or bone marrow to treat specific injuries. The company focuses on developing FDA-approved therapies through clinical trials and research in the regenerative medicine field.
Founders & leadership
EU
Eckhard U. Alt, M.D., Ph.D.Founder
MC
Michael ColemanExecutive
FA
Fabian AltExecutive
RS
Ron StubbersExecutive
Board
BG
Bobby Griffin, MSBoard director
KK
Klaus KellerBoard director
JG
Jerry Griffin, M.D.Board director
Reported raises · per SEC filings
Form D private placements$21.8M disclosed across 5 rounds · 2015–2024
▶$1.7MraisedMar 2024 · 10 investors · BiotechnologyRule 506(b)
▶$1.7MraisedMar 2024 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Amber LangnerDirector
- Jerry GriffinDirector
- Klaus KellerDirector
- Bobby GriffinDirector
- Eckhard AltExecutive Officer, Director
- Fabian AltExecutive Officer, Director
- Offering amount
- $1.7M
- Amount sold
- $1.7M
- First sale
- Feb 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.5MraisedApr 2019 · 1 investors · BiotechnologyRule 506(b)
▶$3.5MraisedApr 2019 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Angelo MoesslangExecutive Officer
- Annette WhiteDirector
- Kelby KrabbenhoftDirector
- Ron StubbersExecutive Officer
- Fabian AltExecutive Officer
- Klaus KellerDirector
- Bobby Griffin, MSDirector
- Eckhard Alt, M.D., Ph.DDirector
- Jerry Griffin, M.D.Director
- Offering amount
- $23M
- Amount sold
- $3.5M
- First sale
- Apr 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$9.9MraisedMar 2017 · 4 investors · BiotechnologyRule 506(b)
▶$9.9MraisedMar 2017 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Fabian AltExecutive Officer
- Eckhard Alt, M.D., Ph.DDirector
- Klaus KellerDirector
- Ron StubbersExecutive Officer
- Bobby Griffin, MSDirector
- Jerry Griffin, M.D.Director
- Offering amount
- $19.9M
- Amount sold
- $9.9M
- Proceeds to insiders
- $300K
- First sale
- Feb 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.1MraisedDec 2016 · 4 investors · BiotechnologyRule 506(b)
▶$2.1MraisedDec 2016 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Fabian AltExecutive Officer
- Jerry Griffin, M.D.Director
- Ron StubbersExecutive Officer
- Klaus KellerDirector
- Eckhard U. Alt, M.D., Ph.D.Director
- Michael ColemanExecutive Officer
- Bobby Griffin, MSDirector
- Offering amount
- $2.1M
- Amount sold
- $2.1M
- Proceeds to insiders
- $100K
- First sale
- Aug 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.5MraisedJul 2016 · 5 investors · BiotechnologyRule 506(b)
▶$4.5MraisedJul 2016 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael ColemanExecutive Officer
- Eckhard U. Alt, M.D., Ph.D.Director
- Bobby Griffin, MSDirector
- Klaus KellerDirector
- Fabian AltExecutive Officer
- Ron StubbersExecutive Officer
- Jerry Griffin, M.D.Director
- Offering amount
- $4.5M
- Amount sold
- $4.5M
- Proceeds to insiders
- $400K
- First sale
- Oct 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlapRegeneron NASDAQ: REGN www.regeneron.com54 shared keywordsRegeneron is a biotechnology company that develops medicines ranging from biologics to genetic medicines to treat serious diseases across areas such as metabolic disease, ophthalmology, and rare disease. The company focuses on research and development driven by human biology, with a clinical trial pipeline addressing conditions like generalized myasthenia gravis.
Eledon22 shared keywordsEledon develops tegoprubart, an anti-CD40L antibody in clinical development for preventing rejection in organ transplant recipients. The company focuses on improving long-term graft survival and quality of life for transplant recipients across kidney, liver, and xenotransplantation.
Bioworld21 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Longeveron19 shared keywordsLongeveron is a clinical-stage biotechnology company developing allogeneic cellular therapies for life-threatening conditions affecting children and the elderly. Its investigational candidate is being evaluated for indications including Hypoplastic Left Heart Syndrome, Pediatric Dilated Cardiomyopathy, Alzheimer's Disease, and age-related frailty.
Companies competing with InGeneron for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does InGeneron do?
- InGeneron develops regenerative cell therapies that use a patient's adult stem cells and other regenerative cells harvested from fat or bone marrow to treat specific injuries. The company focuses on developing FDA-approved therapies through clinical trials and research in the regenerative medicine field.
- Who founded InGeneron?
- InGeneron was founded by Eckhard U. Alt, M.D., Ph.D..
- How much funding has InGeneron raised?
- InGeneron has disclosed $21.8M raised across 5 rounds.
- Where is InGeneron headquartered?
- InGeneron is headquartered in Houston, US.